TOPEKA, Kan. (WIBW) – Kansas State University virologists have identified a potential COVID-19 vaccination.
Kansas State University says Yunjeong Kim and Kyeong-Ok “KC” Chang, virologists in the College of Veterinary Medicine, have published a study showing a possible therapeutic treatment for COVID-19.
K-State says pathogenic coronaviruses are a major threat to global public health, as shown by severe acute respiratory syndrome coronavirus, or SARS-CoV, Middle East respiratory syndrome coronavirus, known as MERS-CoV, and the newly emerged SARS-CoV-2, the virus causing the COVID-19 infection.
The University says the study, “3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice,” appears in the Aug. 3 issue of Science Translational Medicine. It says the study reveals how small molecule protease inhibitors show potency against human coronaviruses. It says these coronavirus 3C-like proteases, known as 3CLpro, are strong therapeutic targets because they play vital roles in coronavirus replication.
“Vaccine developments and treatments are the biggest targets in COVID-19 research, and treatment is really key,” said Chang, professor of diagnostic medicine and pathobiology. “This paper describes protease inhibitors targeting coronavirus 3CLpro, which is a well-known therapeutic target.”
K-State says the study shows the series of optimized coronavirus 3CLpro inhibitors blocked replication of the human coronaviruses MERS-CoV and SARS-CoV-2 in cultured cells and in a mouse model for MERS. It says the findings show this series of compounds should be investigated further as a potential therapeutic for human coronavirus infection.
Chang and Kim say they have been using National Institutes of Health grants to develop antiviral drugs to treat MERS and human norovirus infections. They say their work extends to other human viruses such as rhinoviruses and SARS-CoV-2.
“The work that this group of collaborators has been doing on antivirals and inhibitors for SARS and MERS at K-State for a number of years has been vital to their ability to quickly pivot to emphasize research on SARS-CoV-2 virus and therapeutics,” said Peter K. Dorhout, vice president for research at K-State.
Chang and Kim say they worked with co-collaborators including teams lead by Bill Groutas at Wichita State University, Stanley Perlman at the University of Iowa and Scott Lovell at the University of Kansas.
“Drs. Groutas, Perlman and Lovell brought decades of experience to our research team,” Chang said. “We would not have been able to come this far without important collaborations with our colleagues at other institutions.”
“Getting things published right now is very important for the scientific community,” Kim said. “I think we are adding valuable information to the antiviral field.”
K-State says the new compounds in the publication are exclusively licensed and being developed by Cocrystal Pharma for COVID-19. It says K-State Innovations Partners handles commercial technology licensing for the university.
Copyright 2020 WIBW. All rights reserved.